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he association between thyroid dysfunction and atrial fibrillation (AF) is well known and has been described in both experimental and epidemiological studies. Recently, there has been a growing interest in whether the risk of AF is elevated in milder degrees of thyroid dysfunction, ie, high-normal thyroid function with thyroid-stimulating hormone (TSH) and free thyroxine (fT4) within the normal reference ranges.
1,2 Subclinical hypothyroidism is a common condition with an overall prevalence of 4% in the United States reported by the National Health and Nutrition Examination Survey III, increasing to 10% in the elderly population of the Framingham Study. In general, the prevalence and incidence of subclinical hypothyroidism increases with age, autoimmunity, iodine status, and female sex, and it is associated with several cardiovascular risk factors. [3] [4] [5] In this issue of Circulation, Baumgartner et al 6 from the Thyroid Studies Collaboration present an individual participant data meta-analysis from 11 prospective cohorts, comprising ≈30 000 participants in total. They examined whether the risk of AF was increased in participants with TSH and fT4 levels across the normal reference ranges, and in participants with subclinical hypothyroidism (defined as elevated TSH 4.5-19.9 mIU/L with normal fT4), as well.
The primary finding reported in the study by Baumgartner et al is a 45% higher risk of AF for the highest quartile of fT4 in comparison with the lowest, independent of TSH levels within normal range, even after adjustment for available potential confounders. No association was found between risk of AF and different levels of TSH within the reference range or with subclinical hypothyroidism. It is interesting to note that no association between fT4 and AF was found in the stratified analysis on individuals with previous cardiovascular disease or thyroxine substitution at baseline.
An important finding in this study is that subclinical hypothyroidism was not associated with an increased risk of AF, as also found in the Framingham Heart Study. 7 In a study on patients under primary care, our group even found a 12% lower risk of AF in individuals with subclinical hypothyroidism. 2 The confirmation of previous findings is assuring, although low thyroid function has been associated with cardiovascular risk factors such as dyslipidemia, diastolic hypertension, ventricular diastolic dysfunction, and increased risk of major adverse cardiovascular events in some observational studies. 8, 9 However, so far, there is no evidence that thyroxine substitution therapy has any benefits regarding major adverse cardiovascular events. 10 The study by Baumgartner et al might also help to understand a recent finding that new-onset AF seems to predict future development of hyperthyroidism. 11 Thus, it was found in a Danish nationwide cohort of 145 623 individuals with new-onset AF and no known thyroid dysfunction that the risk of developing subsequent hyperthyroidism was 2-to 3-fold higher during a mean follow-up time of 3.5 years, and it
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can be speculated that new-onset AF could be a signal of mild intracellular increase of thyroid hormone availability or that subclinical hyperthyroidism is being neglected in patients with new-onset AF. 12, 13 That high-normal levels of fT4 were associated with higher AF risk in the present study raises 2 important questions: First, when treating individuals with thyroid dysfunction, should the physician be careful not to achieve a fT4 value at the high end of the normal reference range, especially in the presence of other risk factors for AF? Second, should we have a different goal for fT4 when treating subclinical hypothyroidism? Current guidelines recommend a target of normal/low-normal TSH that often results in fT4 in the high-normal range, which may have adverse effects. 14 Although the study by Baumgartner et al cannot fully answer the questions raised, it underlines the need for intervention trials in this field, because the many observational studies published on this subject have the inherent risk of being biased and the limitations of demonstrating associations without the ability to deduce causal links, and even meta-analysis using individual participant data, carries the risk of selection bias and confounding. In addition, it is difficult when using pooled data from very heterogeneous cohorts to estimate the absolute differences in overall risk and, if a causal link exists between exposure and outcome, how many AF events could potentially be prevented by intervention.
Previous studies have shown that treatment with thyroxine leads to small changes in fT4 but relatively large changes in TSH, and most clinicians therefore focus primarily on TSH and less on fT4. 15 This study challenges this notion to some degree, but does not show that we should abolish TSH as a target when treating individuals with thyroid dysfunction; rather, we probably should give more attention to the fT4 levels in individuals at high risk of AF. Lifestyle modifications and management of known risk factors of AF are important, and this study underlines that it is also important to focus not only on overt thyroid dysfunction, but also on subclinical thyroid dysfunction, which is much more common.
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